Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexdor for Sedation in Pediatric ICU Patients
NCT03813277Phase 4Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine in sedation, sponsored by Orion Corporation. Primary endpoint: Evaluation of efficacy of Dexdor for prolonged sedation in pediatric patients. Started Mar 2017; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
sedation
Beyond the preview
Go deeper on NCT03813277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813277.